Working core outcome measurement set
| Core domain | Outcome measurements | ||
| CLE-specific | Dermatologic | Generic | |
| Skin-Specific Disease Activity | CLASI-A | – | – |
| Investigator Global Assessment of Disease Activity | CLA-IGA* | ||
| Skin-Specific Disease Damage | CLASI-D | – | – |
| Symptoms (pruritus, pain and photosensitivity) | CLEQoL (includes Skindex-29 +3) | DLQI Skindex-29+3 12-Item Pruritus Severity Scale | Itch VAS/NRS Pain VAS/NRS |
| Health-related Quality of Life | CLEQoL (includes Skindex-29 +3) LEQoL | Skindex-29+3 DLQI | SF-36 EQ-5D |
| Patient Global Assessment of Disease Activity | – | – | – |
*May be considered as a secondary or exploratory endpoint, complementary to CLASI, pending ongoing validation.
CLA-IGA, Cutaneous Lupus Activity Investigator’s Global Assessment; CLASI-A, Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity; CLASI-D, Cutaneous Lupus Erythematosus Disease Area and Severity Index-Damage; CLEQoL, Cutaneous Lupus Erythematosus Quality of Life; DLQI, Dermatology Life Quality Index; LEQoL, Lupus Erythematosus Quality of Life Questionnaire; NRS, Numeric Rating Scale; SF-36, Short Form Health Survey; VAS, Visual Analogue Scale.